Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Golidocitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Golidocitinib overview

Golidocitinib (DZD-4205) is under development for the treatment of non-small cell lung cancer and T cell lymphomas including peripheral T cell lymphoma, vascular immunoblast type (AITL), Anaplastic large cell type-ALK positive (ALCL ALK+), anaplastic large cell type-ALK negative (ALCL ALK-); enteropathy-associated T cell lymphoma (EATL), monomorphic epithelial intestinal T cell lymph Tumor (MEITL), NK/T cell lymphoma (NKTCL), liver 44 splenic T cell lymphoma (HSTCL), subcutaneous panniculitis-like T cell lymphoma (SPTCL), relapsed and refractory cutaneous T-cell lymphomas including granuloma fungoides (MF) or Sezary syndrome (SS) It is a small molecule which acts by targeting JAK 1. It is administered through oral route.

Dizal (Jiangsu) Pharmaceutical overview

Dizal (Jiangsu) Pharmaceutical, a pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. The company is headquartered in China.

For a complete picture of Golidocitinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.